1%聚桂醇注射治疗血管瘤血管畸形的Meta分析
发布时间：2019-01-18 12:13
【摘要】：目的本研究旨在通过Meta分析探讨1%聚桂醇瘤体内注射治疗血管瘤及血管畸形的有效性及安全性,进一步明确聚桂醇的治疗作用,为临床合理药物治疗提供循证医学证据。方法按Cochrane系统评价方法,检索Pub Med(建库-2014.12)、Cochrane(建库-2014.12)、Science Direct(SDOS)(建库-2014.12)、相关期刊论文CNKI(1979-2014.12)、重庆维普中文科技期刊数据库VIP(1989-2014.12)、中国生物医学文献数据库CBM(1978-2014.12)、万方数据库(1998-2014.12),语种限中文和英文,纳入已发表的与聚桂醇注射治疗血管瘤血管畸形相关的临床随机对照试验的文献,提取有效数据(有效率、复发率、不良反应发生率),并对提取的数据用Cochrane协作网提供的Rev Man5.2软件进行统计,计算比值比(OR)和95%置信区间(95%CI);如果各项研究存在异质性,分析数据采用随机效应模型进行,如果各项研究不存在异质性或异质性低,则采用固定效应模型进行;发表性偏倚用倒漏斗图分析表示;必要时为检验结果的稳定性可懫用敏感性分析。结果最终共有19篇文献,包含19项临床对照试验(1768个病例)被纳入。采用Rev Man5.2软件进行统计分析结果为:聚桂醇治疗血管瘤及血管畸形的有效率与无水乙醇相比差异无统计学意义(OR=0.34,95%CI:0.05-2.30,P=0.27),不良反应发生率差异无统计学意义(OR=0.33,95%CI:0.14-0.80,P=0.01);聚桂醇治疗血管瘤及血管畸形的有效率与平阳霉素相比差异无统计学意义(OR=0.92,95%CI:0.39-2.16,P=0.85),不良反应发生率低于平阳霉素(OR=0.20,95%CI:0.07-0.58,P=0.003);聚桂醇治疗血管瘤及血管畸形的有效率与介入治疗相比差异无统计学意义(OR=2.01,95%CI:0.85-4.75,P=0.11),不良反应发生率差异无统计学意义(OR=0.29,95%CI:0.09-0.97,P=0.04);聚桂醇治疗血管瘤血管畸形的有效率与激素和普萘洛尔相比差异无统计学意义(OR=2.65,95%CI:0.85-8.31,P=0.09),不良反应发生率差异无统计学意义(OR=0.88,95%CI:0.14-5.57,P=0.89);聚桂醇治疗血管瘤血管畸形的有效率与乙醇胺相比差异无统计学意义(OR=1.49,95%CI:0.12-18.68,P=0.76),不良反应发生率差异亦无统计学意义(OR=1.30,95%CI:0.08-21.90,P=0.86);泡沫型聚桂醇治疗血管瘤血管畸形的有效率与液体型相比差异有统计学意义(RR=1.84,95%CI:1.25-2.72,P=0.002),不良反应发生率差异无统计学意义(OR=0.35,95%CI:0.10-1.19,P=0.09);1%聚桂醇治疗血管瘤血管畸形的有效率与3%聚桂醇相比差异有统计学意义(OR=0.47,95%CI:0.25-0.88,P=0.02),不良反应发生率差异无统计学意义(OR=0.46,95%CI:0.22-0.96,P=0.04)。结论Meta分析的结果表明,对于血管瘤血管畸形的治疗,聚桂醇的疗效疗与其他治疗方法相比无显著优势,但其不良反应发生率低,是一种安全有效的治疗方法。
[Abstract]:Objective to investigate the efficacy and safety of intratumoral injection of 1% polycinnamol in the treatment of hemangioma and vascular malformation by Meta analysis. Methods according to the evaluation method of Cochrane system, we searched the Pub Med (database-2014.12), Cochrane (database-2014.12), Science Direct (SDOS) (database-2014.12) and the Chinese periodical full-text database CNKI (1979-2014.12). VIP (1989-2014.12), CBM (1978-2014.12), Wanfang (1998-2014.12), limited to Chinese and English, To include published literature on clinical randomized controlled trials related to the injection of polycinnamol in the treatment of hemangioma vascular malformation, and to extract effective data (effective rate, recurrence rate, incidence of adverse reactions), The extracted data are counted by Rev Man5.2 software provided by Cochrane cooperation network, and the ratio is calculated by (OR) and 95% confidence interval (95%CI). If heterogeneity exists in each study, random effect model is used to analyze the data, if there is no heterogeneity or heterogeneity is low in each study, fixed effect model is used, publication bias is expressed by inverted funnel graph analysis. Sensitivity analysis can be used if necessary for the stability of the test results. Results A total of 19 articles including 19 clinical controlled trials (1768 cases) were included. The results of statistical analysis with Rev Man5.2 software were as follows: the effective rate of polycinnamol in treating hemangioma and vascular malformation had no statistical significance (OR=0.34,95%CI:0.05-2.30,P=0.27) compared with anhydrous alcohol. There was no significant difference in the incidence of adverse reactions (OR=0.33,95%CI:0.14-0.80,P=0.01). There was no significant difference (OR=0.92,95%CI:0.39-2.16,P=0.85) between polycinnamol and pingyangmycin in the treatment of hemangioma and vascular malformation. The incidence of adverse reactions was lower than that of pingyangmycin (OR=0.20,95%CI:0.07-0.58,P=0.003). The effective rate of polycinnamol in treating hemangioma and vascular malformation was not significantly different from that of interventional therapy (OR=2.01,95%CI:0.85-4.75,P=0.11). There was no significant difference in the incidence of adverse reactions (OR=0.29,95%CI:0.09-0.97,P=0.04). The effective rate of polycinnamol in the treatment of hemangioma vascular malformation was not significantly different from that of hormone and propranolol (OR=2.65,95%CI:0.85-8.31,P=0.09). There was no significant difference in the incidence of adverse reactions (OR=0.88,95%CI:0.14-5.57,P=0.89). There was no significant difference (OR=1.49,95%CI:0.12-18.68,P=0.76) between polycinnamol and ethanolamine in the treatment of hemangioma vascular malformation. There was no significant difference in the incidence of adverse reactions (OR=1.30,95%CI:0.08-21.90,P=0.86). The effective rate of foam polycinnamol in the treatment of hemangioma vascular malformation was significantly different from that of liquid type (RR=1.84,95%CI:1.25-2.72,P=0.002). There was no significant difference in the incidence of adverse reactions (OR=0.35,95%CI:0.10-1.19,P=0.09). The effective rate of 1% polycinnamol in the treatment of hemangioma vascular malformation was significantly higher than that in 3% polycinnamol (OR=0.47,95%CI:0.25-0.88,P=0.02). There was no significant difference in the incidence of adverse reactions (OR=0.46,95%CI:0.22-0.96,P=0.04). Conclusion the results of Meta analysis show that polycinnamol has no significant advantage in the treatment of hemangioma vascular malformation, but its adverse reaction rate is low, so it is a safe and effective treatment method.
【学位授予单位】：安徽医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R654.3
本文编号：2410708
[Abstract]:Objective to investigate the efficacy and safety of intratumoral injection of 1% polycinnamol in the treatment of hemangioma and vascular malformation by Meta analysis. Methods according to the evaluation method of Cochrane system, we searched the Pub Med (database-2014.12), Cochrane (database-2014.12), Science Direct (SDOS) (database-2014.12) and the Chinese periodical full-text database CNKI (1979-2014.12). VIP (1989-2014.12), CBM (1978-2014.12), Wanfang (1998-2014.12), limited to Chinese and English, To include published literature on clinical randomized controlled trials related to the injection of polycinnamol in the treatment of hemangioma vascular malformation, and to extract effective data (effective rate, recurrence rate, incidence of adverse reactions), The extracted data are counted by Rev Man5.2 software provided by Cochrane cooperation network, and the ratio is calculated by (OR) and 95% confidence interval (95%CI). If heterogeneity exists in each study, random effect model is used to analyze the data, if there is no heterogeneity or heterogeneity is low in each study, fixed effect model is used, publication bias is expressed by inverted funnel graph analysis. Sensitivity analysis can be used if necessary for the stability of the test results. Results A total of 19 articles including 19 clinical controlled trials (1768 cases) were included. The results of statistical analysis with Rev Man5.2 software were as follows: the effective rate of polycinnamol in treating hemangioma and vascular malformation had no statistical significance (OR=0.34,95%CI:0.05-2.30,P=0.27) compared with anhydrous alcohol. There was no significant difference in the incidence of adverse reactions (OR=0.33,95%CI:0.14-0.80,P=0.01). There was no significant difference (OR=0.92,95%CI:0.39-2.16,P=0.85) between polycinnamol and pingyangmycin in the treatment of hemangioma and vascular malformation. The incidence of adverse reactions was lower than that of pingyangmycin (OR=0.20,95%CI:0.07-0.58,P=0.003). The effective rate of polycinnamol in treating hemangioma and vascular malformation was not significantly different from that of interventional therapy (OR=2.01,95%CI:0.85-4.75,P=0.11). There was no significant difference in the incidence of adverse reactions (OR=0.29,95%CI:0.09-0.97,P=0.04). The effective rate of polycinnamol in the treatment of hemangioma vascular malformation was not significantly different from that of hormone and propranolol (OR=2.65,95%CI:0.85-8.31,P=0.09). There was no significant difference in the incidence of adverse reactions (OR=0.88,95%CI:0.14-5.57,P=0.89). There was no significant difference (OR=1.49,95%CI:0.12-18.68,P=0.76) between polycinnamol and ethanolamine in the treatment of hemangioma vascular malformation. There was no significant difference in the incidence of adverse reactions (OR=1.30,95%CI:0.08-21.90,P=0.86). The effective rate of foam polycinnamol in the treatment of hemangioma vascular malformation was significantly different from that of liquid type (RR=1.84,95%CI:1.25-2.72,P=0.002). There was no significant difference in the incidence of adverse reactions (OR=0.35,95%CI:0.10-1.19,P=0.09). The effective rate of 1% polycinnamol in the treatment of hemangioma vascular malformation was significantly higher than that in 3% polycinnamol (OR=0.47,95%CI:0.25-0.88,P=0.02). There was no significant difference in the incidence of adverse reactions (OR=0.46,95%CI:0.22-0.96,P=0.04). Conclusion the results of Meta analysis show that polycinnamol has no significant advantage in the treatment of hemangioma vascular malformation, but its adverse reaction rate is low, so it is a safe and effective treatment method.
【学位授予单位】：安徽医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R654.3
【参考文献】
相关期刊论文 前1条
1 张洪涛;叶涛;;平阳霉素联合聚桂醇治疗口腔颌面部血管瘤的临床疗效评价[J];实用临床医药杂志;2013年09期
，本文编号：2410708
本文链接：https://www.wllwen.com/yixuelunwen/waikelunwen/2410708.html
最近更新
教材专著
